{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:47:49Z","timestamp":1792043269317,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Celgene, a Bristol-Myers Squibb Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor T-cell therapy, showed high response rates and favorable safety in patients with relapsed\/refractory (R\/R) FL in the international, pivotal, phase 2 study (TRANSCEND FL). We report results from TRANSCEND FL in Japanese patients with second-line or later (2L+) FL after a median on-study follow-up of 31\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Key eligibility criteria were age \u226518\u00a0years, prior combination systemic therapy including an anti-CD20 antibody and alkylating agent, and positron emission tomography\u2013positive, measurable lesions. Primary endpoint was overall response rate (ORR) per independent review committee using Lugano 2014 criteria. Secondary endpoints included complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 10 Japanese patients received liso-cel and were evaluated for safety; 9 were efficacy-evaluable. Patients had a median age of 67\u00a0years and a median of 3 prior systemic therapies. ORR and CR rate (95% CI) were both 100% (66.4\u2013100). Median DOR and PFS were not reached, 24-month DOR and PFS rates (95% CI) were both 88.9% (43.3\u201398.4), and only 1 patient had relapsed. All patients were alive at data cutoff. Rates of any-grade cytokine release syndrome (CRS), neurological events (NEs), and infections were 30%, 10%, and 30%, respectively; no grade \u22653 CRS, NEs, or infections were reported. No new safety signals were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data underscore liso-cel as an effective treatment option with a manageable safety profile for Japanese patients with 2L+ R\/R FL.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration number<\/jats:italic>\n                      NCT04245839.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03199-5","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:15:22Z","timestamp":1792041322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-8088","authenticated-orcid":false,"given":"Shinichi","family":"Makita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-9973","authenticated-orcid":false,"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-535X","authenticated-orcid":false,"given":"Yuichi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Strocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Ghodke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"3199_CR1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E (2022) Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 97:1638\u20131651. https:\/\/doi.org\/10.1002\/ajh.26737","journal-title":"Am J Hematol"},{"key":"3199_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536\u2013545. https:\/\/doi.org\/10.1111\/bjh.12659","journal-title":"Br J Haematol"},{"key":"3199_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/jcm12041417","volume":"12","author":"LC Chiu","year":"2023","unstructured":"Chiu LC, Lin CW, Li HJ et al (2023) Incidence trend of follicular lymphoma in Taiwan compared to Japan and Korea, 2001\u20132019. J Clin Med 12:1417. https:\/\/doi.org\/10.3390\/jcm12041417","journal-title":"J Clin Med"},{"key":"3199_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","volume":"13","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Mu\u00f1oz J, Trotman J (2024) Current and future therapies for follicular lymphoma. Exp Hematol Oncol 13:87. https:\/\/doi.org\/10.1186\/s40164-024-00551-1","journal-title":"Exp Hematol Oncol"},{"key":"3199_CR5","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1097\/hs9.0000000000000745","volume":"6","author":"G Salles","year":"2022","unstructured":"Salles G, Schuster SJ, Fischer L et al (2022) A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL). Hemasphere 6:e745. https:\/\/doi.org\/10.1097\/hs9.0000000000000745","journal-title":"Hemasphere"},{"key":"3199_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12185-025-03922-4","volume":"121","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Fukuhara N (2025) JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma-1. Follicular lymphoma (FL). Int J Hematol 121:577\u2013585. https:\/\/doi.org\/10.1007\/s12185-025-03922-4","journal-title":"Int J Hematol"},{"key":"3199_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516\u20132522. https:\/\/doi.org\/10.1200\/jco.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"3199_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0140-6736(25)01778-7","volume":"407","author":"LH Sehn","year":"2026","unstructured":"Sehn LH, H\u00fcbel K, Luminari S et al (2026) Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet 407:133\u2013146. https:\/\/doi.org\/10.1016\/s0140-6736(25)01778-7","journal-title":"Lancet"},{"key":"3199_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0140-6736(25)02360-8","volume":"407","author":"L Falchi","year":"2026","unstructured":"Falchi L, Nijland M, Huang H et al (2026) Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet 407:161\u2013173. https:\/\/doi.org\/10.1016\/s0140-6736(25)02360-8","journal-title":"Lancet"},{"key":"3199_CR10","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1182\/bloodadvances.2024014975","volume":"9","author":"NN Shah","year":"2025","unstructured":"Shah NN, Zinzani PL, Wang M et al (2025) Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study. Blood Adv 9:5954\u20135964. https:\/\/doi.org\/10.1182\/bloodadvances.2024014975","journal-title":"Blood Adv"},{"key":"3199_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/s1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A et al (2020) Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433\u20131442. https:\/\/doi.org\/10.1016\/s1470-2045(20)30441-1","journal-title":"Lancet Oncol"},{"issue":"33","key":"3199_CR12","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1200\/jco-25-00668","volume":"43","author":"SS Neelapu","year":"2025","unstructured":"Neelapu SS, Chavez JC, Sehgal AR et al (2025) Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma. J Clin Oncol 43:3573\u20133577. https:\/\/doi.org\/10.1200\/jco-25-00668","journal-title":"J Clin Oncol"},{"key":"3199_CR13","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML et al (2024) Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med 30:2199\u20132207. https:\/\/doi.org\/10.1038\/s41591-024-02986-9","journal-title":"Nat Med"},{"key":"3199_CR14","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-cell lymphomas V.1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed Apr 24, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"3199_CR15","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel). Full prescribing information. Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; February 2026. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_breyanzi.pdf. Accessed Apr 17, 2026."},{"key":"3199_CR16","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel). Full prescribing information. Bristol-Myers Squibb. April 2026. Available at: https:\/\/www.pmda.go.jp\/PmdaSearch\/saiseiDetail\/ResultDataSetPDF\/670605_4900406X1029_A_02_08. Accessed Apr 17 2026."},{"key":"3199_CR17","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2024-198509","volume":"144","author":"L Nastoupil","year":"2024","unstructured":"Nastoupil L, Dahiya S, Palomba ML et al (2024) Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Transcend FL 2-year follow-up. Blood 144:4387\u20134390. https:\/\/doi.org\/10.1182\/blood-2024-198509","journal-title":"Blood"},{"key":"3199_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"3199_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3\u201311. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05094.x","journal-title":"Br J Haematol"},{"key":"3199_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"3199_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/jco.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A et al (2024) Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol 42:205\u2013217. https:\/\/doi.org\/10.1200\/jco.23.01097","journal-title":"J Clin Oncol"},{"key":"3199_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR et al (2024) Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143:496\u2013506. https:\/\/doi.org\/10.1182\/blood.2023021243","journal-title":"Blood"},{"key":"3199_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12185-022-03481-y","volume":"117","author":"N Fukuhara","year":"2023","unstructured":"Fukuhara N, Kato K, Goto H et al (2023) Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. Int J Hematol 117:251\u2013259. https:\/\/doi.org\/10.1007\/s12185-022-03481-y","journal-title":"Int J Hematol"},{"key":"3199_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10147-024-02662-5","volume":"30","author":"H Goto","year":"2025","unstructured":"Goto H, Kumode T, Mishima Y et al (2025) Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed\/refractory follicular lymphoma: FLMOON-1. Int J Clin Oncol 30:389\u2013396. https:\/\/doi.org\/10.1007\/s10147-024-02662-5","journal-title":"Int J Clin Oncol"},{"key":"3199_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10147-025-02957-1","volume":"31","author":"S Makita","year":"2026","unstructured":"Makita S, Izutsu K, Mishima Y et al (2026) Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed\/refractory follicular lymphoma. Int J Clin Oncol 31:456\u2013466. https:\/\/doi.org\/10.1007\/s10147-025-02957-1","journal-title":"Int J Clin Oncol"},{"key":"3199_CR26","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/10428194.2025.2525983","volume":"66","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Akahane D, Toubai T et al (2025) Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma 66:1913\u20131921. https:\/\/doi.org\/10.1080\/10428194.2025.2525983","journal-title":"Leuk Lymphoma"},{"key":"3199_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH et al (2012) Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15:940\u2013947. https:\/\/doi.org\/10.1016\/j.jval.2012.05.004","journal-title":"Value Health"},{"key":"3199_CR28","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1182\/blood-2024-197948","volume":"144","author":"AP Boardman","year":"2024","unstructured":"Boardman AP, Reguera JL, Spin P et al (2024) Matching-adjusted indirect comparison (MAIC) of efficacy and safety outcomes for lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for the treatment of third-line or later (3L+) relapsed or refractory (R\/R) follicular lymphoma (FL). Blood 144:3028\u20133029. https:\/\/doi.org\/10.1182\/blood-2024-197948","journal-title":"Blood"},{"key":"3199_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","volume":"14","author":"LJ Nastoupil","year":"2025","unstructured":"Nastoupil LJ, Bonner A, Wang P et al (2025) Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Exp Hematol Oncol 14:30. https:\/\/doi.org\/10.1186\/s40164-025-00610-1","journal-title":"Exp Hematol Oncol"},{"key":"3199_CR30","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1182\/blood.2025029909","volume":"146","author":"L Falchi","year":"2025","unstructured":"Falchi L, Sureda A, Lepp\u00e4 S et al (2025) Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood 146:2629\u20132640. https:\/\/doi.org\/10.1182\/blood.2025029909","journal-title":"Blood"},{"key":"3199_CR31","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J et al (2022) Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 139:1684\u20131693. https:\/\/doi.org\/10.1182\/blood.2020010263","journal-title":"Blood"},{"key":"3199_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12185-026-04219-w","volume":"124","author":"R Nishiyama","year":"2026","unstructured":"Nishiyama R, Hiratsuka A, Ochi T et al (2026) T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel. Int J Hematol 124:413\u2013421. https:\/\/doi.org\/10.1007\/s12185-026-04219-w","journal-title":"Int J Hematol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03199-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03199-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03199-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:15:23Z","timestamp":1792041323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03199-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":32,"alternative-id":["3199"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03199-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shinichi Makita reports honoraria from Bristol Myers Squibb, Chugai Pharmaceutical, Gilead, and Genmab. Hideki Goto reports honoraria from AbbVie, Bristol Myers Squibb, Genmab, Kite\/Gilead, Kyowa-Kirin, and Novartis; and research funding from Bristol Myers Squibb, Kyowa-Kirin, Sanofi, and SymBio Pharmaceuticals. Koji Izutsu reports consulting fees from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Genmab, GlaxoSmithKline, Kyowa-Kirin, Mitsubishi Tanabe Pharma, Merck Sharp & Dohme, Nippon Shinyaku, Ono Pharmaceutical, Otsuka, Takeda, and Zenyaku Kogyo; honoraria from AbbVie, AstraZeneca, BeOne Medicines, BeiGene, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Genmab, Gilead Sciences, Janssen, Kyowa-Kirin, Lilly, Meiji Seika Kaisha, Merck Sharp & Dohme, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka, Pfizer, Recordati, SymBio Pharmaceuticals, and Takeda; and research funding from Chugai Pharmaceutical and Eisai. Yuichi Baba is an employee and holds stock in Bristol Myers Squibb. Merav Bar is an employee and holds stock in Bristol Myers Squibb. Maria Strocchia is an employee and holds stock in Bristol Myers Squibb. Prachi Ghodke is an employee of Syneos Health. Rina Nishii is an employee and holds stock in Bristol Myers Squibb. Takanori Teshima reports honoraria from AbbVie, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Janssen Pharmaceutical, Kyowa-Kirin, Nippon Shinyaku, and Novartis; and research funding from AbbVie, Chugai Pharmaceutical, CMIC, CSL Behring, Gilead Sciences, International Advanced Medical Organization, IQVIA, Janssen, Kyowa-Kirin, LUCA Science, Novartis, Pharma Essentia Japan, and Priothera SAS.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}